Adovate was named as a recipient of a Virginia Catalyst grant award. This grant is to fund the Phase 2 human studies in asthma patients of our lead compound, ADO-5030. Thank you to our collaborators and world-leading researchers Dr. Larry Borish at the University of Virginia, and Dr. Liwu Li at Virginia Tech. We are excited to continue our work with them on this important program to develop an effective treatment for the 30-50% of asthma patients that are unresponsive to steroids, the current first-line therapy, as well as being a potential treatment for all asthma patients. A link to the press release is attached. #Adovate #VirginiaCatalyst #GrantAward #Biosciences #Innovation #Healthcare #asthma #Research #EconomicGrowth #Collaboration #UVA #VirginiaTech
Adovate’s Post
More Relevant Posts
-
We're thrilled to announce the theme of the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS)) Forum 2024: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗶𝗻 𝗠𝗦. This pivotal event will take place from February 29 to March 2 in West Palm Beach, Florida. The Forum's scientific program promises to be a deep dive into the challenges facing MS treatment and research today. Discussions will encompass a range of critical barriers, including healthcare disparities, access to care, CNS borders and associated cells, obstacles to neural repair, rehabilitation roadblocks, and clinical trial design considerations. 🗓 In a special session on Friday March 1st, 𝗣𝗥𝗢𝗠𝗦 𝗶𝘀 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗵𝗮𝗿𝗰𝗼𝘁 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 - 𝗠𝗼𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝘁 𝘁𝗵𝗲 𝗖𝗲𝗻𝘁𝗲𝗿, scheduled for 1:30 PM - 2:30 PM EST. The symposium will be expertly chaired by Giancarlo Comi (PROMS Co-Chair Executive Committee) and Mark Freedman from the University of Ottawa. Our distinguished representatives will share invaluable insights. Paola Zaratin (SSC Co-Chair) will present “𝗙𝗿𝗼𝗺 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗮𝗻𝗱 𝗩𝗶𝗰𝗲-𝗩𝗲𝗿𝘀𝗮: 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 𝗟𝗲𝗮𝗿𝗻𝗲𝗱 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗣𝗥𝗢𝗠𝗦 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲”. Letizia Leocani (WG3 Co-Leader) will delve into “𝗔𝗿𝗲 𝗪𝗲𝗮𝗿𝗮𝗯𝗹𝗲 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝘁𝘂𝗿𝗲 𝘁𝗼 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 𝗠𝗦?” Following, Robert McBurney (WG2 Co-leader) will discuss “𝗣𝗥𝗢𝘀 𝗶𝗻 𝗠𝗦 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗶𝗲𝘀 𝗮𝗻𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗖𝗮𝗿𝗲”. This is a prime opportunity to revisit the core messages of the PROMS initiative, which has made significant strides and continues to focus on science of patient-engagement growth in the field. For more details, check out the full program here: https://lnkd.in/diCHUkUj #𝗔𝗖𝗧𝗥𝗜𝗠𝗦𝗙𝗼𝗿𝘂𝗺 #MS #MultipleSclerosis #HealthcareInnovation #𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗖𝗲𝗻𝘁𝗲𝗿𝗲𝗱𝗖𝗮𝗿𝗲
To view or add a comment, sign in
-
Thanks Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) and European Charcot Foundation, for fostering further global collaboration on Global PROMS Initiative, maximizing science with and for patient input. Together we are stronger! The time is right to: * Enable deep phenotyping of pwMS experiential knowledge for the use of appropriate Patient-Reported Outcome Measures (PROMs) towards personalized medicine. * Develop targeted approaches with relevant PROMs to ensure that clinical trials and clinical practice are aligned with patient values. * Enable digital technologies to capture PROMs changes over time. * Standardize the use of valid, reliable, and responsive PRO measures, via MS Registers data sharing, for their targeted – personalized – use. Special thanks to @Professor Mark Freedman, Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) President, and Conference Chair Professor Daniel Ontaneda for his valuable expert partnership in the Global PROMS Initiative mission.
We're thrilled to announce the theme of the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS)) Forum 2024: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗶𝗻 𝗠𝗦. This pivotal event will take place from February 29 to March 2 in West Palm Beach, Florida. The Forum's scientific program promises to be a deep dive into the challenges facing MS treatment and research today. Discussions will encompass a range of critical barriers, including healthcare disparities, access to care, CNS borders and associated cells, obstacles to neural repair, rehabilitation roadblocks, and clinical trial design considerations. 🗓 In a special session on Friday March 1st, 𝗣𝗥𝗢𝗠𝗦 𝗶𝘀 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗵𝗮𝗿𝗰𝗼𝘁 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 - 𝗠𝗼𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝘁 𝘁𝗵𝗲 𝗖𝗲𝗻𝘁𝗲𝗿, scheduled for 1:30 PM - 2:30 PM EST. The symposium will be expertly chaired by Giancarlo Comi (PROMS Co-Chair Executive Committee) and Mark Freedman from the University of Ottawa. Our distinguished representatives will share invaluable insights. Paola Zaratin (SSC Co-Chair) will present “𝗙𝗿𝗼𝗺 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗮𝗻𝗱 𝗩𝗶𝗰𝗲-𝗩𝗲𝗿𝘀𝗮: 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 𝗟𝗲𝗮𝗿𝗻𝗲𝗱 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗣𝗥𝗢𝗠𝗦 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲”. Letizia Leocani (WG3 Co-Leader) will delve into “𝗔𝗿𝗲 𝗪𝗲𝗮𝗿𝗮𝗯𝗹𝗲 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝘁𝘂𝗿𝗲 𝘁𝗼 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 𝗠𝗦?” Following, Robert McBurney (WG2 Co-leader) will discuss “𝗣𝗥𝗢𝘀 𝗶𝗻 𝗠𝗦 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗶𝗲𝘀 𝗮𝗻𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗖𝗮𝗿𝗲”. This is a prime opportunity to revisit the core messages of the PROMS initiative, which has made significant strides and continues to focus on science of patient-engagement growth in the field. For more details, check out the full program here: https://lnkd.in/diCHUkUj #𝗔𝗖𝗧𝗥𝗜𝗠𝗦𝗙𝗼𝗿𝘂𝗺 #MS #MultipleSclerosis #HealthcareInnovation #𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗖𝗲𝗻𝘁𝗲𝗿𝗲𝗱𝗖𝗮𝗿𝗲
To view or add a comment, sign in
-
💙 #G2PRunning4Research (Meet Our Runners): Erin Drake, Director of Research Operations. Read the purpose behind Erin's fundraising initiative for Genomes2People's #Running4Research! 👇 🏃🏻♀️"I am running because I love our Genomes2People Research Program team and I love the work that we do. I am inspired by the brilliance, motivation, productivity, dedication, and genuine camaraderie we experience together at work each day. We are striving toward a day when onset of disease can be predicted and prevented through the power of genomics and precision medicine at the population level. Your support of our team's efforts in running a 10K to earn $10K will help us tremendously as we work toward our research and clinical goals." In the picture: Bethany Zettler, MS, CGC (L) and Erin Drake (R). One stride closer to the finish line: https://lnkd.in/gFZ3grwr #Genomes2People #10kMarathon #Boston #BostonMarathon #Research #HealthResearch #TranslationalResearch #Science #ScientificResearch #TranslationalScience #Genetics #DNA #Genes #PreventiveGenetics #GeneticResearch #Genome #Genomes #Genomics #PreventiveGenomics #TranslationalGenomics #GeneticTesting #GeneticCounseling #GeneticCounselors #Geneticists #MedicalGeneticists #Screening #Sequencing #NewbornSequencing #DNASequencing #WholeGenomeSequencing #Health #PrecisionHealth #PublicHealth #PopulationHealth #NewbornHealth #ChildrenHealth #PreventiveHealth #PreventativeHealth #PersonalizedHealth #HealthForAll #HealthEquity #EvidenceBasedMedicine #HealthOutcomes #Healthcare #PreventiveHealthcare #PersonalizedHealthcare #HealthcareInnovation #Medicine #EquitableMedicine #PrecisionMedicine #PreventiveMedicine #Engineering #Technology #MedTech #PreventativeMedicine #PersonalizedMedicine #GenomicMedicine #BioMedicine #Biology #Biotechnology #Biomedical #HealthSciences #HealthCommunication #ScienceCommunication #SciComm #Philanthropy #GoodCause
To view or add a comment, sign in
-
💡 Actuated Medical, Inc. won a $331,416 award from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases! 🎉 💡 This Phase I SBIR award is for the development of a photoacoustic tool to improve visualization and success rates in sacral neural modulation lead placement. The goal is to create a system that enables real-time visualization and guidance control to direct sacral neurostimulation leads adjacent to the sacral nerve, improving implantation accuracy and outcomes for people with bladder or bowel incontinence. 📊 This research is a project grant (B) that will last for 0.92 years, starting from July 15, 2024, and ending on June 30, 2025. The research type is Grant/Subgrant/Subcontract. Congratulations to Actuated Medical on this achievement! #SBIR #STTR #MedicalInnovation #HealthcareTechnology
To view or add a comment, sign in
-
Human Advocate for Equity in Access and Informed Decision Making | Integrity, Ethics, Inclusion and Transparency by Design | Enabling Co-Creation for a Healthier Future for all | Global R&D Collaborations | Convergence
The star of the show isT.J. Sharpe and the reality of why we are still having this exhaustive conversation... is because of courageous humans like you and bewildered humans like me! Thank you so very much for changing my focus when I heard you speak for the first time almost 9 years ago. There is simply no more appropriate perspective than the lived human clinical trial participant and healthcare human experience in demonstrating the WHY NOT!! Informed decision making requires a commitment to ensuring the timely sharing of linked health data generated by patients/study participants wherever they are on their care journey and helps all stakeholders understand the patient experience, the evolution of patient safety, product effectiveness over time and valuable evidence generation. Solutions to ensure a risk-based, meaningful, pro-active, ethical approaches/options for the return of individual participant data and lay summaries demonstrates reciprocity, respect and partnership, requires global harmonization and flexibility and has the ability to transform the cultural thinking about what is possible when we critically think and re-think about our shared mutual objectives, reducing burden on health systems and patients to accelerate medicines development. Essential to ensuring the sustainability of R&D and improving global health equity. Providing pragmatic personalized options which matter most to patients and their care providers and securing mechanisms that will facilitate the convergence of clinical care and clinical research is no longer an option. #DIA2024 Session #373 Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) Innovative Health Initiative (IHI) Facilitate Project TransCelerate BioPharma Inc. Society for Clinical Research Sites (SCRS) CISCRP #pfdd #CRACO #Collaborating with #patients to enable a healthier future for all. Enabling #innovation and #equity ambitions through co-creation and global collaboration. #datasharing #patientsaspartners #healthinformation #bioethics
Patient engagement clinical research advocate expert with a decade+ of industry-advocacy experience. Stage IV melanoma survivor. Keynote speaker. JV football coach.
Coming to #DIA2024? Mark session #373 on your Wednesday calendar for the one-time-only showing of "Patient-Centric Approaches in Summaries and Data Return" starring Jean Stimola-Sposaro, MSJ, with yours truly riding shotgun on this docu-drama focused on "How in the world is information return STILL not happening and WHAT the heck are we doing about it?" Featuring the work of TransCelerate BioPharma Inc., Clinical Trials Transformation Initiative (CTTI), Innovative Health Initiative (IHI), Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center), and others. Get your 🍿 !! https://lnkd.in/eYhJEmry #PatientDataReturn #IRR #RoR #LaySummaries
To view or add a comment, sign in
-
Join us at #UEGWeek where Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will present data on target achievement in patients with moderate to severe ulcerative colitis participating in the VERDICT study, a trial focused on evaluating different algorithms of achieving treatment target in ulcerative colitis. Stop by booth #57 to learn more about our innovative research! #Alimentiv #IBD #ClinicalResearch
To view or add a comment, sign in
-
Professor of the Department of Community Medicine, Information and Health Decision Sciences of Faculdade de Medicina da Universidade do Porto and of Oral and Maxillofacial Medicine at Case Western Reserve University
NEW DEADLINE: submission of abstracts for the 3rd OPMDay has been extended until April 14th: https://lnkd.in/d2-jrv_n The OPMDay is a two-day conference focusing on #oralpotentiallymalignantdisorders (OPMDs) and the flagship event of INTERCEPTOR, a project financed by the COST Association - European Cooperation in Science and Technology. Abstracts must fall under one of the following categories: “original studies”, “work-in-progress”, “new trial ideas/concepts”, and “study proposals seeking new collaborations”. Submissions by #youngresearchers and #students is strongly encouraged. The goal is to foster networking and collaboration among experts in the field of #oralcancer #prevention and to develop a new multidisciplinary approach that may help to reorganize disease care management, while fostering support for #patients affected by OPMD and enhancing the #prevention of #malignant transformation of these lesions. This year's meeting will be hosted at the Faculdade de Medicina da Universidade do Porto. Save the date: https://lnkd.in/d95G-Gch
To view or add a comment, sign in
-
Our CEO John Ford, CMO Renu Gupta, M.D, Head of Development Paul Russell, Head of Biology Henry Danahay and COO/CSO Martin Gosling will be at the North American Cystic Fibrosis Conference (NACFC) conference in Boston next week. Bringing together scientists, clinicians and caregivers from around the globe to discuss the most recent developments in #CF research, care and #drugdevelopment, the aim of this conference is to improve the health and quality of life of people with #CF. Learn more about NACFC and the Cystic Fibrosis Foundation here: https://bit.ly/4cxGbbu If you’re interested to hear more about our lead candidate ETD001, designed to treat people with #CF with the highest unmet medical need, why not arrange a meeting with us: 📧 info@enterprisetherapeutics.com
To view or add a comment, sign in
-
Today, kicks off our 4th annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, hosted by #LupusTherapeutics, the clinical affiliate of the Lupus Research Alliance. This annual meeting brings people with #lupus together with thought leaders, clinical investigators, study coordinators, research & industry partners to discuss the progress and advancements being made in #LupusClinicalResearch and treatment, and the importance of health equity and access in #lupus clinical trials. Learn more about LuCIN at https://bit.ly/LuCIN2024 #LuCINCommunity #LupusAwarenessMonth
To view or add a comment, sign in
-
Business Development @hVIVO world leader in human challenge trials | Infectious & Respiratory Diseases | Entrepreneur | Industry Consultant | Forbes Council Member | Women Leadership | Speaker | Longevity Enthusiast♾️
After numerous discussions with clients about their #Asthma and #COPD clinical trials at the European Respiratory Society Congress, I have decided to share this info with a broader audience and start a post series on the 6 biggest challenges in the respiratory disease clinical research. Number one major challenge is the disparity between the recruitment targets and the actual number of patients enrolled. Delays in subject recruitment can disrupt study timelines and inflate costs. Some sites, despite best efforts, find it difficult to reach the targeted numbers. This leads to extended recruitment periods, increased expenses, and delayed study completion. Contributing factors include continued access to specific phenotype populations, difficult inclusion and exclusion criteria, and low engagement of patients. hVIVO employs data-driven recruitment strategies to provide realistic patient recruitment projections, ensuring that studies meet their targets on time without overpromising. By utilizing FluCamp recruitment arm, the database of around 80.000 subjects with #respiratorydiseases and latest technology solutions, we can navigate through the list of highly engaged patient population, ready to be enrolled in #clinicaltrials. Stay tuned for more! #hvo
To view or add a comment, sign in
159 followers
Professor of Medicine at McGill University
9moWell done to all concerned, especially to Liwu, an Editor of Inflammation Research.